---
title: "Asahi Kasei Pharma and Alchemedicine progress AK1960 to Phase I trial for refractory diseases treatment."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276236679.md"
description: "A joint effort between Asahi Kasei Pharma and Alchemedicine has led to the progression of AK1960 to a Phase I clinical trial in Tokyo. The partnership marks a significant milestone in the research and development process. The compound AK1960 is now undergoing testing involving a group of participants, signifying a crucial step forward in the pharmaceutical field. This advancement highlights the promising potential of AK1960, showing promise for potential future medical applications."
datetime: "2026-02-18T13:37:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276236679.md)
  - [en](https://longbridge.com/en/news/276236679.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276236679.md)
generator: "portal-rs"
---

# Asahi Kasei Pharma and Alchemedicine progress AK1960 to Phase I trial for refractory diseases treatment.

A joint effort between Asahi Kasei Pharma and Alchemedicine has led to the progression of AK1960 to a Phase I clinical trial in Tokyo. The partnership marks a significant milestone in the research and development process. The compound AK1960 is now undergoing testing involving a group of participants, signifying a crucial step forward in the pharmaceutical field. This advancement highlights the promising potential of AK1960, showing promise for potential future medical applications.

### Related Stocks

- [AHKSY.US](https://longbridge.com/en/quote/AHKSY.US.md)

## Related News & Research

- [Asahi Kasei expands Kawasaki electrolyzer, chlor-alkali equipment capacity to at least 2 GW each by 2028](https://longbridge.com/en/news/296290110.md)
- [Asahi Kasei licenses Acetolyte electrolyte technology to HighChem Shanghai in China](https://longbridge.com/en/news/295042465.md)
- [North Sea Crude-WTI weakens on lower offer](https://longbridge.com/en/news/296813963.md)
- [Nvidia Earnings: Wall Street Expects Growth to Slow in Q2 — Dan Niles Says Hyperscalers Are Spending Like Never Before](https://longbridge.com/en/news/296822352.md)
- [There’s More to Consider, Says Investor About Sandisk Stock](https://longbridge.com/en/news/296795615.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**